Patent ID: 8877756

Claim:
A method of treating chronic obstructive pulmonary disease (COPD) or asthma, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula 1, wherein: R 1 is pyrrolidinyl; R 2 is piperazinyl; and R 3 is NHR 3.1 or OR 3.1 , wherein R 3.1 is H or a group selected from branched or unbranched alkyl with 1 to 6 carbon atoms substituted by one or more hydroxyl groups, C 1-6 -haloalkyl, C 1-6 -alkylene-O—C 1-2 -alkyl, a mono- or bicyclic, saturated or partially unsaturated C 3-10 -cycloalkyl, mono- or bicyclic, saturated or partially saturated, four-to ten-membered heterocyclic group with 1 to 3 heteroatoms selected from S, N, or O, and a mono- or bicyclic, five- to ten-membered heteroaromatic group with 1 to 4 heteroatoms selected from S, N, or O, which may optionally be substituted by one or more groups selected from among OH, halogen, C 1-6 -alkyl, branched or unbranched alkyl with 1 to 6 carbon atoms substituted by one or more hydroxyl groups, C 1-6 -haloalkyl, COOR 3.3 , O—C 1-6 -alkyl, C 6-10 -aryl, C 3-10 -cycloalkyl, four- to ten-membered heterocyclic group, five- to ten-membered heteroaromatic group, and O—C 1-4 -alkyl-henyl, wherein this group is optionally substituted by one or more groups selected from halogen, OH, C 1-3 -alkyl, and C 1-3 -haloalkyl, and wherein R 3.3 is H, C 1-6 -alkyl, or branched or unbranched alkyl with 1 to 6 carbon atoms substituted by one or more hydroxyl groups, or R 3 is a saturated or partially saturated, bi- or polycyclic seven-, eight-, nine-, or ten-membered heterocyclic group containing a nitrogen atom and optionally containing one, two, or three other atoms selected from S, N, and O and which are optionally substituted by one or more groups selected from OH, halogen, C 1-6 -alkyl, branched or unbranched alkyl with 1 to 6 carbon atoms substituted by one or more hydroxyl groups, C 14 -alkyl-O—C 1-3 -alkyl, C 6-10 -aryl, C 3-10 -cycloalkyl, five- to ten-membered heteroaryl, four- to ten-membered heterocyclic group, C 1-2 -alkylene-C 5-10 -heteroaryl, and C 1-2 -alkylene-C 4-10 heterocycle, each of which are optionally substituted by one or more groups selected from methyl, ethyl, O-methyl, Cl, F, and OH, and the pharmacologically acceptable salts, diastereomers, enantiomers, and racemates thereof.